Integrin Approaches to Combat Ocular Neovascularization

Time: 2:30 pm
day: Day Two


  • Pre-clinical and clinical studies have shown that several integrins, including αvβ3 are expressed in neovascular ocular tissue from patients with nAMD & DR/DME, making them an attractive alternative target for nAMD & DR/DME therapeutics
  • This presentation will focus on novel integrin approaches as an alternative target for angiogenesis derived diseases